All In Biotech

Drug Trial Radar · NCT07768592

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD)

A Proof-of-Mechanism, Open-Label, Parallel Group Study With an Open-Label Extension Phase to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

May 6, 2030

Study completion May 6, 2030

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Aug 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate proof of mechanism (POM) and long-term safety and tolerability of E2511 in participants with Early AD. The study consists of 2 parts. In Part A, participants will be randomly assigned to receive either E2511 or donepezil. In Part B, participants will receive E2511 only. Once Part A and Part B participants complete the Core Trial (which includes Pretreatment and Treatment phases) they will have the option to enter the Extension Phase where they will receive E2511 for 18 months.

Conditions

  • Alzheimers Disease

Interventions

  • E2511Drug

    E2511 oral tablets.

  • DonepezilDrug

    Donepezil oral tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A (Core Trial): Change from Baseline in [11C]MK-6884 Positron Emission Tomography (PET) Using Non-Displaceable Binding Potential (BPND) at 14 DaysTime frame: Baseline up to Day 14
  2. Part A and B (Extension Phase): Number of Participants With Adverse Events (AEs)Time frame: Up to 91 weeks
  3. Part A and B (Extension Phase): Number of Participants With Clinically Significant Changes in Vital Sign ValuesTime frame: From Week 13 up to Week 91
  4. Part A and B (Extension Phase): Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) ValuesTime frame: From Week 13 up to Week 91
  5. Part A and B (Extension Phase): Number of Participants With Clinically Significant Changes in Physical ExamTime frame: From Week 13 up to Week 91
  6. Part A and B (Extension Phase): Number of Participants With Clinically Significant Changes in Neurological ExamTime frame: From Week 13 up to Week 91
  7. Part A and B (Extension Phase): Number of Participants With Clinically Significant Changes in Laboratory Safety Tests ValuesTime frame: From Week 13 up to Week 91
  8. Part A and B (Extension Phase): Number of Participants With Suicidality as Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS)Time frame: Up to 91 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.